Weak Sales and a Recall of Daptomycin Reported

Weak Sales and a Recall of Daptomycin Reported

Daptomycin, recognized as the brand name antibiotic Cubicin, has a patent expiration of September 24, 2019. Cubist Pharmaceutical markets Cubicin and they recently released a report revealing surprisingly weak sales. Initially Cubist reported strong sales of Daptomycin for the first quarter of 2013, with an overall rise in their revenues due to this potent antibiotic. However, just a year later the story is quite different. While net sales of Daptomycin increased 9.4% to $202 million in the first quarter of 2013, sales of Cubicin {Daptomycin} fell 14.7 percent in the first quarter of 2014. Coupled with a recall for Lot # 280453F of Cubicin on April 18, 2014 due to suspected glass particulates, Cubist Pharmaceuticals is now looking to turn their situation around.

Daptomycin CAS 103060-53-3

Daptomycin is approved in the United States as well as in several other countries to treat serious bacterial, blood and skin or underlying tissue infections. This powerful antibiotic should not be given to patients who have severe kidney disease or are on dialysis. Patients who take certain drugs, specifically warfarin (Coumadin), atorvastatin (Lipitor, Caduet), fluvastatin (Lescol), lovastatin (Mevacor, Altoprev, Advicor), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin (Zocor, Simcor, Vytorin) and tobramycin (Nebcin) should not be administered Daptomycin without vigorous monitoring for severe adverse effects. Daptomycin is dispensed as an Intravenous Infusion and is typically administered every 24 hours. The time frame for dosing ranges from seven to ten days, depending on the type and severity of infection. Many patients are in a hospital setting or outpatient environment when they receive their dosing of Daptomycin. Side effects may include headache, nausea, back pain, vomiting and increased sweating.

LGM Pharma supplies Daptomycin, CAS number 103060-53-3, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.








  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service